23:45:29 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-05-12 Ordinarie utdelning ATANA 0.00 SEK
2025-05-09 Kvartalsrapport 2025-Q1
2025-05-09 Årsstämma 2025
2025-02-21 Bokslutskommuniké 2024
2024-11-22 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-03 Kvartalsrapport 2024-Q1
2024-05-03 Årsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-08 Ordinarie utdelning ATANA 0.00 SEK
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2022-12-07 Extra Bolagsstämma 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-09 Ordinarie utdelning ATANA 0.00 SEK
2022-05-06 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-10 Ordinarie utdelning ATANA 0.00 SEK
2021-05-07 Kvartalsrapport 2021-Q1
2021-05-07 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-11-09 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-11 Ordinarie utdelning ATANA 0.00 SEK
2020-05-08 Kvartalsrapport 2020-Q1
2020-05-08 Årsstämma 2020
2020-02-24 Bokslutskommuniké 2019
2019-11-29 Kvartalsrapport 2019-Q3
2019-08-09 Extra Bolagsstämma 2019
2019-08-07 Kvartalsrapport 2019-Q2
2019-05-08 Ordinarie utdelning ATANA 0.00 SEK
2019-05-07 Kvartalsrapport 2019-Q1
2019-04-05 Årsstämma 2019
2019-02-26 Bokslutskommuniké 2018
2018-05-08 Ordinarie utdelning ATANA 0.00 SEK
2018-05-07 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriLäkemedel & Handel
Attana bedriver forskning och utveckling av läkemedel. Bolaget specialiserar sig inom biologisk interaktionskarakterisering, som används för analys i utvecklandet av nya läkemedel. Bolagets patenterade lösningar används vid studerandet av bindningsegenskaper och makrostrukturer i celler, proteiner, virus och bakterier. Verksamhet återfinns främst inom Norden och Europa. Bolaget grundades under 2002 och har sitt huvudkontor i Stockholm.
2020-10-21 13:16:22

The shareholders in Attana AB, org. no. 556931-4106 (the "Company"), are hereby invited to the Extraordinary General Meeting on Monday, November 9, 2020 at 10.00 at the Company's office, Greta Arwidssons Väg 21, 114 19 Stockholm.

REGISTRATION AND NOTICE TO ATTEND

Shareholders who wish to participate in the Extraordinary General Meeting shall:

(i) be recorded in the share register kept by Euroclear Sweden AB on Friday, on October 30, 2020, and

(ii) notify its intention to participate in the Extraordinary General Meeting to the Company no later than Monday, November 2, 2020.

Registration is made to the Company's e-mail: ir@attana.comor in writing to the Company's address; Attana AB, Greta Arwidssons Väg 21, 114 19 Stockholm. Upon registering, the name, personal or organization number, address, telephone number and number of any attendees or accompanying advisors, if any, must be stated.

NOMINEE SHARES

Shareholders whose shares are registered in the name of a nominee must temporarily re-register their shares in their own names in the share register maintained by Euroclear Sweden AB in order to be entitled to attend and vote at the Extraordinary General Meeting. Such registration must be completed with Euroclear Sweden AB no later than Tuesday, November 3, 2020 and must therefore be requested from the nominee well in advance of this date.

PROXY ETC

Shareholders represented by proxy must submit a written, signed and dated power of attorney. If the power of attorney is issued by a legal entity, a certification of registration or an equivalent authorization document must be attached. The original version of the power of attorney and the certificate of registration, if applicable, shall be sent to the Company to the abovementioned address well in advance of the Extraordinary General Meeting. A template proxy form is available on the Company's website, www.attana.com.

PROPOSED AGENDA

1. Opening of the meeting.
2. Election of chairman of the meeting.
3. Preparation and approval of the voting list.
4. Election of one or two persons to verify the minutes.
5. Determination of whether the meeting has been duly convened.
6. Approval of the agenda.
7. Presentation of documents in accordance with the Swedish Companies Act (sw. Aktiebolagslagen (2005:551) Section 13 Clause 6. 
8. Resolution on preferential right issue.
9. Resolution on authorizing the board of directors to decide on an overallotment share issue. 
10. Closing of the meeting.

PROPOSED RESOLUTIONS

Item 8 - Resolution on preferential right issue

The board of directors proposes that the Extra General Meeting resolves to increase the Company's share capital by a maximum of SEK 292,323.40 by, subject to the shareholders' preferential rights, an share issue of a maximum of 48,705,400 shares (the "Preferential Rights Issue").

The share issue shall be addressed to existing shareholders, pro rata their shareholding on the record date, who, with the support of their preferential rights, shall have the right to subscribe for shares. Each share in the Company entitles to one (1) subscription right and seven (7) subscription rights entitle to subscription for two (2) new shares.

The subscription price amounts to SEK 1.30 per share. The new shares will be subscribed for during the period 3 - 17 December 2020. The record date is 2 December 2020.

The Preferential Rights Issue is conditional on the Company receiving approval from the Swedish Financial Supervisory Authority (sw. Finansinspektionen) of a prospectus for the Preferential Right Issue.

Item 9 - Resolution on authorizing the board of directors to decide on an overallotment share issue

The board of directors also proposes that the Extraordinary General Meeting resolves to authorize the board of directors to, within six (6) months of the decision on the Preferential Rights Issue, on one occasion, and with deviation from the shareholders' preferential rights, decide on an overallotment of shares to the subscribers in the Preferential Rights Issue who did not receive full allocation therein. The board of directors shall then have the right to decide that the shares issued in the overallotment share issue shall be paid for in the form of cash payment or by setting-off claims against the Company. The issue price and other issue terms shall (in addition to the above) correspond to the terms of the Preferential Rights Issue. The board of directors' decision on the overallotment share issue may in total comprise a maximum increase of the Company's share capital of SEK 60,000 and a maximum of 10,000,000 shares.

The purpose of the authorization of an overallotment share issue and the reasons for deviating from the shareholders' preferential rights is to satisfy a possible oversubscription in the Preferential Rights Issue and thereby provide the Company with additional capital.

MAJORITY REQUIREMENT

A resolution in accordance with the board of directors' proposal under item 9 above requires that the resolution is decided by shareholders representing at least two thirds (2/3) of both the votes cast and the shares represented at the Extra General Meeting.

DOCUMENTATION

The complete proposal under item 8, a copy of the Company's annual report, the auditor's report and the board of directors report on significant events of the Company's financial position and the auditor's opinion on it will be available to the shareholders of the Company at the above address and on the Company's website www.attana.com no later than 2 weeks before the Extra General Meeting. The documents are also sent free of charge to the shareholders who request it from the Company and state their address.

____________________

Stockholm October 2020

Attana AB

The board of directors